SA
Log In
AMBUJACEM.NS
OverviewIntelligenceChart

No data available

Earnings in 1 day · May 4, 2026
Signal
Bearish Setup2↓
Price
1↓
Move↓-2.34%Negative session
Volume
1→
Volume→1.2× avgNormal activity
Technical
1↓
Trend↓Full DowntrendBelow 50D & 200D
PRICE
Prev Close
454.60
Open
450.20
Day Range440.10 – 450.20
440.10
450.20
52W Range394.00 – 624.95
394.00
624.95
22% of range
VOLUME & SIZE
Avg Volume
2.7M
Float
2.5B
FUNDAMENTALS
P/E Ratio
29.7x
EPS (TTM)
$14.97
Div Yield
No dividend
Quick Read
Earnings Tomorrow · May 4
Trend
DOWNTREND
Price below SMA50 & SMA200
Momentum
BULLISH
revenue +18% YoY · 69% gross margin
Valuation
EXPENSIVE
P/E 30x vs ~20x sector
Health
MODERATE
CR 1.1 · FCF negative
Neutral
Key MetricsTTM
Market Cap$1.10T
Revenue TTM$390.22B
Net Income TTM$37.14B
Free Cash Flow$0.00
Gross Margin69.0%
Net Margin9.5%
Operating Margin8.7%
Return on Equity6.4%
Return on Assets4.2%
Debt / Equity0.02
Current Ratio1.07
EPS TTM$15.02
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong1 watch3 concern
49/100
Liquidity
1.07Watch
Leverage
0.02Strong
Coverage
15.7xStrong
ROE
6.4%Concern
ROIC
4.5%Concern
Cash
$50.4BConcern
Analyst Coverage

No analyst coverage available for this stock.

Stock Health
Composite Score
0 of 6 signals bullish
1/10
Trend
●
Trend StateDowntrend (below both MAs)
✗
●
Above SMA 50$449.90 (-1.3%)
✗
●
Above SMA 200$531.59 (-16.5%)
✗
Technicals
●
MA AlignmentDeath Cross (50D vs 200D -15.4%)
✗
Fundamentals
●
Last EarningsMissed estimates
✗
●
LiquidityCurrent Ratio 1.07
~
Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
PDividend PaymentOct 29, 2026
In 179 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Market Position
Price Levels
52W High
$625.0+40.8%
SMA 200
$531.6+19.7%
SMA 50
$449.9+1.3%
Current
$443.9
52W Low
$394.0-11.3%
52-Week RangeNear 52-week low
$394.022th %ile$625.0
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 35 analysts
Full estimates →
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$351.9B
$337.1B–$408.2B
—$14.25—
±45%
High28
FY2026(current)
$416.4B
$402.1B–$446.9B
▲ +18.3%$12.64▼ -11.3%
±33%
High35
FY2027
$477.0B
$450.8B–$520.4B
▲ +14.6%$14.41▲ +14.0%
±50%
High35
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryAMBUJACEM.NS
Last 8Q
-7.8%avg beat
Beat 3 of 8 quartersMissed 5
-34%
Q2'24
-43%
Q3'24
+8%
Q4'24
+14%
Q2'25
-20%
Q3'25
+176%
Q4'25
-82%
Q1'26
-82%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Financials
Dividends0.45% yield
+17.9% avg annual growth
Annual Yield0.45%
Annual Div.$2.0000
Est. Annual / Share$2.00
FrequencyAnnual
Q1'19
Q2'20
Q4'20
Q1'21
Q1'22
Q3'23
Q2'24
Q2'25

Dividend per payment — last 8 periods

News & Activity

AMBUJACEM.NS News

20 articles · 4h ago

About

No company information available

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance